Hikal Q1 FY27 Results 2026: Loss Narrows, Revenue Up

Results announcement and why it matters

Hikal Limited has reported its unaudited financial results for the quarter ended June 30, 2026, marking the first quarter of FY2026-27 (Q1 FY27). The company disclosed that it posted a standalone net loss of ₹7.5 crore for the period. The quarter is important because it shows a sharper split between performance in the Pharmaceuticals segment and pressure in the Crop Protection segment. The results were cleared through the company’s governance process, with the Audit Committee reviewing the numbers on August 05, 2026, and the Board approving them on August 06, 2026.

In addition, the statutory auditor, S R B C & Co LLP, issued an unmodified limited review report under Regulation 33 of the SEBI (LODR) Regulations, 2015, as disclosed by the company. Hikal also scheduled an earnings conference call on August 06, 2026 at 5:00 PM IST to discuss quarterly performance.

Key headline numbers for Q1 FY27

For the quarter ended June 30, 2026, Hikal reported revenue from operations of ₹402.8 crore (₹4,028 million). In another disclosure, revenue from operations was stated at ₹399.8 crore (₹3,998 million), indicating a narrow difference across referenced extracts. The company reported a standalone net loss of ₹7.5 crore (₹75 million) for the quarter.

On a sequential and year-on-year basis, the article data also points to a volatile profit trend. The same set of disclosures compares Q1 FY27 to a profit of ₹14.6 crore (₹146 million) in the preceding quarter ended March 31, 2026, and a standalone loss of ₹22.7 crore (₹227 million) in the corresponding quarter ended June 30, 2025. On the revenue line, Q1 FY27 revenue of ₹402.8 crore is stated as lower than ₹519.4 crore (₹5,194 million) in the preceding quarter, and slightly higher than ₹380.4 crore (₹3,804 million) in the year-ago quarter.

Profit before tax and the role of exceptional items

Hikal’s quarterly disclosures include profit before tax (PBT) numbers before and after exceptional items. For the quarter, PBT before exceptional items was reported at a loss of ₹18.9 crore (₹189 million). After exceptional items, PBT was reported at a loss of ₹10.0 crore (₹100 million) in one extract, while another extract states loss before tax after exceptional items of ₹9.9 crore (₹99 million).

The article data also flags that exceptional items had a meaningful effect on PBT for the quarter. It specifically mentions an ₹8.9 crore (₹89 million) reduction in employee benefit liabilities due to salary restructuring, described as a favourable exceptional item that supported the narrowing of losses.

Expense mix: materials and other costs

On the cost side, the company reported cost of materials consumed at ₹194.0 crore (₹1,940 million). Other expenses were disclosed at ₹110.0 crore (₹1,100 million). The article data also mentions employee benefits expense of ₹74.4 crore (₹744 million) in the consolidated context.

While the disclosures point to “notable changes” in expenses, the clearest takeaway from the numbers shared is that input and operating costs remained significant relative to quarterly revenue. The quarter also reflects how a one-time favourable exceptional line can change the shape of reported profitability even when operating performance remains under pressure.

Comprehensive income and EPS snapshot

Hikal reported other comprehensive income of ₹0.2 crore (₹2 million) for the period. Consequently, total comprehensive income or loss for the quarter was reported at a loss of ₹7.3 crore (₹73 million) in one disclosure. Another extract states the total comprehensive income attributable to equity holders of the parent was a loss of ₹7.2 crore (₹72 million).

Earnings per share (EPS) was disclosed as a loss for the quarter. One set of numbers reports basic and diluted EPS at ₹(0.61), while another mentions basic and diluted EPS at ₹(0.60). These EPS figures align with the reported net loss outcome for the quarter.

Segment performance: Pharmaceuticals vs Crop Protection

The segment disclosures in the article show a clear split between Pharmaceuticals and Crop Protection. In one segment-wise set, Pharmaceuticals reported revenue from operations of ₹233.3 crore (₹2,333 million) and profit before tax of ₹7.5 crore (₹75 million). Crop Protection reported revenue from operations of ₹169.5 crore (₹1,695 million) and a loss before tax of ₹6.0 crore (₹60 million).

Another extract, described as a standalone segment-wise analysis, reports Pharmaceuticals profit before tax at ₹1.5 crore (₹15 million) and Crop Protection loss before tax at ₹8.9 crore (₹89 million). Taken together, the disclosures consistently indicate that Pharmaceuticals was profitable at the PBT level, while Crop Protection remained loss-making during the quarter, though the exact segment PBT figures vary across referenced extracts.

Corporate actions and compliance updates

Hikal said the trading window for designated persons was closed from July 01, 2026, and is set to re-open on August 09, 2026. The company also disclosed the earnings conference call schedule for August 06, 2026 at 5:00 PM IST. The call was stated to be facilitated by Strategic Growth Advisors Pvt. Ltd., and participation from senior leadership was indicated, including Vice Chairman and Managing Director Sameer Hiremath and CFO Kuldeep Jain.

The article data also includes dial-in numbers for the earnings call across regions, along with RSVP email contacts for investor queries. These details typically matter for institutional investors tracking management commentary beyond the headline numbers.

Summary table: numbers disclosed in the article

Market context and what investors tracked this quarter

The article data characterises the quarter as one where the consolidated net loss narrowed to ₹7.4 crore from ₹22.4 crore year-on-year, alongside revenue growth of 6% year-on-year to ₹402.8 crore. It also notes that operational performance improved in key segments, while Crop Protection faced regulatory pressures and remained loss-making at the PBT level.

From an investor lens, the combination of segment divergence and exceptional items is central to reading the quarter. Pharmaceuticals delivering PBT profits provides support to the overall result, while Crop Protection losses continue to pull consolidated performance lower. The presence of a favourable exceptional gain linked to employee benefit liabilities also means investors may focus on management commentary for the underlying run-rate.

Conclusion and next confirmed event

Hikal’s Q1 FY27 disclosures show revenue around ₹403 crore and a standalone net loss of ₹7.5 crore, with Pharmaceuticals profitable and Crop Protection in loss. The Audit Committee review (August 05, 2026), Board approval (August 06, 2026), and an unmodified limited review report form the compliance backbone of the update.

The next confirmed milestone is the company’s scheduled earnings conference call on August 06, 2026 at 5:00 PM IST, where management is expected to discuss quarterly financial and operational performance based on the published results.